Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Conforti

Showing results (21-30 of 101) with videos related to

Pageof 11
Sort By:
Frontiers in Immunology|July 5, 2022
Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex FactorsPei Pei Chong, Joshua B Rubin, Maha Abdullah, et al.
Therapeutic Advances in Medical Oncology|August 22, 2020
Successful treatment with avapritinib in patient with mucosal metastatic melanomaEmilia Cocorocchio, Laura Pala, Fabio Conforti, et al.
The Lancet. Oncology|August 14, 2018
Sex as a predictor of response to cancer immunotherapy - Authors' replyFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2018
Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the MicrobiomeLaura Pala, Luigi Nezi, Tommaso De Pas, et al.
European Urology|September 19, 2018
Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database ConsortiumFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Cancers|April 14, 2025
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic ResponsesJacopo Canzian, Fabio Conforti, Flavia Jacobs, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
First Report of Pembrolizumab Activity in KIT-Mutated Thymic CarcinomaTommaso Martino De Pas, Giuseppe Giaccone, Chiara Catania, et al.
The Lancet. Oncology|May 21, 2018
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysisFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Seminars in Oncology|December 3, 2024
Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancerLaura Pala, Tommaso De Pas, Emilia Cocorocchio, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|January 28, 2022
Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysisGiovanni Corso, Oriana D'Ecclesiis, Francesca Magnoni, et al.
Pageof 11

Showing results (21-30 of 101) with videos related to

Sort By:
Pageof 11
Frontiers in Immunology|July 5, 2022
Editorial: Differential Efficacy of Immune Checkpoint Inhibitors due to Age and Sex FactorsPei Pei Chong, Joshua B Rubin, Maha Abdullah, et al.
Therapeutic Advances in Medical Oncology|August 22, 2020
Successful treatment with avapritinib in patient with mucosal metastatic melanomaEmilia Cocorocchio, Laura Pala, Fabio Conforti, et al.
The Lancet. Oncology|August 14, 2018
Sex as a predictor of response to cancer immunotherapy - Authors' replyFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2018
Sex Differences in Efficacy and Toxicity of Systemic Cancer Treatments: Role of the MicrobiomeLaura Pala, Luigi Nezi, Tommaso De Pas, et al.
European Urology|September 19, 2018
Reply to Jeffrey Graham, Omar Abdel-Rahman, Toni K. Choueiri, and Daniel Y.C. Heng's Letter to the Editor re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database ConsortiumFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Cancers|April 14, 2025
Sex-Related Differences in Immunotherapy Toxicities: Insights into Dimorphic ResponsesJacopo Canzian, Fabio Conforti, Flavia Jacobs, et al.
Current Oncology (Toronto, Ont.)|February 25, 2025
First Report of Pembrolizumab Activity in KIT-Mutated Thymic CarcinomaTommaso Martino De Pas, Giuseppe Giaccone, Chiara Catania, et al.
The Lancet. Oncology|May 21, 2018
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysisFabio Conforti, Laura Pala, Vincenzo Bagnardi, et al.
Seminars in Oncology|December 3, 2024
Gender-based differences in the efficacy of anti-EGFR/BRAF/MEK targeted therapy in patients with BRAF-mutated metastatic colorectal cancerLaura Pala, Tommaso De Pas, Emilia Cocorocchio, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|January 28, 2022
Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysisGiovanni Corso, Oriana D'Ecclesiis, Francesca Magnoni, et al.
Pageof 11